title: Monoclonal antibodies for treating multiple myeloma - a new era, new safety considerations?
authors.affiliation: a Myeloma Unit, Division of Hematology , University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino , Torino , Italy.
authors.forename: Stefania
authors.initials: S
authors.lastname: Oliva
authors.affiliation: a Myeloma Unit, Division of Hematology , University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino , Torino , Italy.
authors.forename: Antonio
authors.initials: A
authors.lastname: Palumbo
mesh_terms: D051997:ADP-ribosyl Cyclase 1 / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D015195:Drug Design; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000276:immunology; D000071176:Signaling Lymphocytic Activation Molecule Family / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; C448987:SLAMF7 protein, human; D000071176:Signaling Lymphocytic Activation Molecule Family; D051997:ADP-ribosyl Cyclase 1
keywords: Multiple myeloma; daratumumab; elotuzumab; monoclonal antibodies; safety